This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
PICO
Question: Among inner-city children with inadequately controlled asthma, does omalizumab (anti-IgE) provide significant added benefit to usual therapy?
Question type: Therapy
Study design: Randomized, double-blind, parallel
A randomized, doubleblind placebo-controlled, parallel-group, multicenter trial of omalizumab (a humanized anti-IgE) was conducted in 419 inner-city children, adolescents, and young adults, aged 6 to 20 years in several United States cities by investigators from 10 States and Washington, DC. Criteria for inclusion included at least one positive skin test to a perennial allergen and poorly controlled asthma as indicated by hospitalization or unscheduled urgent care in the 6 to 12 months preceding study entry. Additionally, body weight and total IgE had to be within …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.